Lavaca Capital’s Acceleron Pharma XLRN Stock Holding History

Lavaca Capital’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-60	Closed	-$3K	–	388
2019 Q1	$3K	Hold	60	–	–	﹤0.01%	353
2018 Q4	$3K	Buy	+60	New	+$3K	﹤0.01%	326

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Lavaca Capital's XLRN Position: Q2 2019 in Review

Lavaca Capital sold out of Acceleron Pharma (XLRN) in Q2 2019, closing a stake of 60 shares — an estimated $3K sold.

Lavaca Capital first reported a position in XLRN in Q4 2018 and held it in 2 quarters. The position peaked at $3K in Q1 2019. 166 funds tracked by Wall St. Rank hold XLRN as of Q2 2019.

Lavaca Capital reported no remaining Acceleron Pharma position as of Q2 2019 after selling out during the quarter.
Lavaca Capital sold 60 Acceleron Pharma shares in Q2 2019, an estimated $3K.
Lavaca Capital first reported a position in Acceleron Pharma in Q4 2018 and held it in 2 quarters.
Lavaca Capital's Acceleron Pharma position peaked at $3K in Q1 2019.
166 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2019.

Based on Lavaca Capital's 13F filing for Q2 2019, filed 29 Jul 2019.